Role Of Novel Penetration Enhancer in The Transdermal Patch of Naproxen Sodium for Dysmenorrhea Management

This research were investigates the role of a novel penetration enhancer (Quercetin) in enhancing the transdermal delivery of Naproxen Sodium for the management of dysmenorrhea, a common gynaecological condition characterized by painful menstrual cramps. Naproxen Sodium, a nonsteroidal anti-inflammatory drug (NSAID), is widely used for its analgesic and anti-inflammatory properties in alleviating menstrual pain. However, its oral administration is associated with gastrointestinal side effects, and there is a need for alternative routes of administration to improve therapeutic outcomes and patient compliance. The formulation development phase involves the preparation of transdermal patches containing Naproxen Sodium and the novel penetration enhancer. The penetration enhancer is selected based on its ability to increase drug permeation through the skin barrier without compromising its integrity or causing irritation. The transdermal patches of Naproxen Sodium was formulated by using solvent casting method. The patches was evaluated for its physicochemical properties, including thickness, uniformity, adhesive strength, and drug content uniformity. The drug content of transdermal patches was found to be in the range of 88.70 ±0.4 % to 97.12 ±0.5 %. In vitro permeation studies are conducted using Franz diffusion cells to investigate the permeation kinetics of Naproxen Sodium across synthetic membrane barriers and excised chicken skin sample. The drug release through experiments was found to be in the range of 76.00 ± 0.3 % to 91.13 ± 0.2 %. In vitro skin permeation studies also carried out permeation enhancement in presence of quercetin was found to be 47.11%. The developed transdermal patch has the potential to provide sustained and controlled drug delivery, offering a promising therapeutic option for women suffering from dysmenorrhea.